Advanced NanoTherapies, a Los Gatos, CA-based clinical-stage medical device company, raised $4M in funding.
The round saw participation from an undisclosed medical device company.
The company intends to use the funds to share angiographic data from its ADVANCE-DCB FIH trial in early 2024.
Led by CEO Marwan Berrada, Advanced NanoTherapies is a specialized medical device company developing a nanoparticle technology-based platform for drug delivery. It is focused on minimally invasive cardiovascular applications to bring a safer therapeutic option to patients with coronary artery disease (CAD) or peripheral artery disease (PAD). The company’s first product is the SirPlux Duo DCB, a CAD and PAD front-line therapy.
The SirPlux Duo DCB combines the synergistic power of sirolimus and paclitaxel to create a front-line therapy engineered to provide stent-like patency and restenosis prevention while leaving no implant behind. The DCB delivers low-dose, long-term release of both compounds to inhibit cell growth, resulting in maximum potency exceeding other DCBs or drug-eluting stents.1 The ANT nanoparticle drug-encapsulation and delivery platform is designed to provide safe, reliable, and sustained bioavailability of the two synergistic drugs in tissue.
The company plans to share angiographic data from its ADVANCE-DCB FIH trial in early 2024.
FinSMEs
22/08/2023
References
1. Data on file at ANT